Congress Reauthorizes Rare Pediatric Disease PRV Program: A Major Win for 30 million Americans
On February 3, 2026, U.S. Congress delivered a major victory for the rare disease community with the five-year reauthorization of the Rare Pediatric Disease Priority Review Voucher (PRV) Program alongside increased federal research funding and several patient-centered healthcare reforms.
What Is the Rare Pediatric Disease PRV Program and why does It Matter?
The Rare Pediatric Disease Priority Review Voucher (PRV) Program, established by the U.S. Food and Drug Administration (FDA) over a decade ago, was designed to incentivize drug development for rare pediatric conditions.
Here’s how it works:
When a company develops and gains approval for a treatment targeting a rare pediatric disease, it receives a priority review voucher.
That voucher can be used to accelerate FDA review for another drug or sold to another company.
The program costs taxpayers nothing.
But it significantly increases investment in therapies that otherwise might never be developed.
To date, it has helped advance treatments for more than 40 rare pediatric diseases, many of which would not have attracted commercial funding without this incentive.
After a two-year lapse, the program’s reauthorization means:
Clinical trials that were paused can resume.
Investment decisions that were on hold can move forward.
Biotech innovation pipelines can reopen for rare pediatric conditions.
For families who have waited years for therapy options, this restart matters.
Increased NIH Funding: A Critical Research Boost
In another important development, the National Institutes of Health (NIH) will receive $48.7 billion for FY26, an increase of $415 million.
Within that:
The National Center for Advancing Translational Sciences (NCATS), the NIH’s hub for rare disease research, receives a $10 million increase specifically dedicated to rare diseases.
Protections were included against drastic cuts to NIH indirect costs.
A proposed change that would have reduced the number of grants awarded annually was blocked.
At a time when research funding has faced uncertainty, these protections send a clear message: rare disease research remains a national priority.
Additional Patient-Centered Wins in the Legislation
1. The Accelerating Kids Access to Care Act
Makes it easier for physicians to enroll in out-of-state Medicaid programs
Helps children with rare diseases access specialized care across state lines
2. The Give Kids a Chance Act
Expands pediatric cancer funding
Clarifies exclusivity under the Orphan Drug Act
Strengthens FDA authority in generic drug development
Includes continued support for the PRV Program
3. ARPA-H Funding
The Advanced Research Projects Agency for Health (ARPA-H) will receive $1.5 billion to continue high-risk, high-reward research initiatives including work aimed at improving rare disease diagnosis and therapy development.
4. Newborn Screening Support
The Centers for Disease Control and Prevention (CDC) will maintain funding to support state newborn screening programs, ensuring early identification of rare conditions where early intervention can be lifesaving.
5. Joe Fiandra Access to Home Infusion Act
Expands Medicare coverage for home infusion services
Allows patients with rare diseases to receive infused medications at home instead of traveling to hospitals
6. Telehealth Extensions
Medicare telehealth flexibilities are extended through December 31, 2027, allowing:
Care from home
Audio-only visits
Expanded provider eligibility
7. PBM Reform
Policies now:
Increase price transparency
Require pharmacy benefit managers to pass rebate savings to employers
Improve pharmacy network adequacy
8. Community Health Centers
The bill includes the largest increase in mandatory funding for community health centers in the past decade, strengthening frontline access to care.
Why This Moment Matters?
The reauthorization of the PRV Program, along with renewed investments in critical health research and public health initiatives, marks an important milestone for the rare disease community. In a complex and rapidly evolving legislative environment, this achievement reflects the collective strength and persistence of patients, families, advocates, researchers, and policymakers who have worked tirelessly despite uncertainty and shifting priorities to advance these policies.
Sustained national investments in biomedical research, public health infrastructure, and programs like the PRV Program have helped transform scientific possibility into tangible progress for many of the 30 million Americans living with rare diseases. These efforts demonstrate the power of collaboration and the importance of continued commitment to advance rare disease research and innovation.
Although much work remains to support everyone living with a rare disease, today’s progress will help accelerate innovation, expand access to life-changing therapies, and offer renewed hope to children and families.
